PFE

Pfizer
D

PFE

Arincen59/100B

Pfizer debt to equity ratio

Pfizer's debt to equity ratio is 0.70: total debt of 62.67B USD against shareholders' equity of 89.00B USD.

Today
0.70
Average, 5 years
0.63
Low, 5 years
0.35
High, 5 years
0.80

Debt to equity = total debt ÷ shareholders' equity = 62.67B ÷ 89.00B = 0.70

Debt to equity
Total debt
Shareholders' equity

Total debt over shareholders' equity at each quarter end.

Debt to equity by year and by quarter

Fiscal yearPeriod endingDebt to equityTotal debtShareholders' equity
Today0.7062.67B89.00B
FY202531 Dec 20250.7867.42B86.48B
FY202431 Dec 20240.7666.99B88.20B
FY202331 Dec 20230.8070.85B89.01B
FY202231 Dec 20220.3634.86B95.66B
FY202131 Dec 20210.4837.00B77.20B
FY202031 Dec 20200.6138.27B63.24B
FY201931 Dec 20190.8150.84B63.14B
FY201831 Dec 20180.6641.75B63.41B
FY201731 Dec 20170.6042.61B71.31B
FY201631 Dec 20160.6941.06B59.54B
FY201531 Dec 20150.6038.90B64.72B
FY201431 Dec 20140.5136.68B71.30B
FY201331 Dec 20130.4836.49B76.31B
FY201231 Dec 20120.4637.46B81.26B
FY201131 Dec 20110.4738.94B82.19B
FY201031 Dec 20100.5044.03B87.81B
FY200931 Dec 20090.5448.66B90.01B
FY200831 Dec 20080.3017.28B57.56B
FY200731 Dec 20070.2013.14B65.01B
FY200631 Dec 20060.117.98B71.36B
FY200531 Dec 20050.2717.94B65.63B
FY200431 Dec 20040.2718.55B68.28B
FY200331 Dec 20030.2214.57B65.38B
FY200231 Dec 20020.5911.81B19.95B
FY200131 Dec 20010.488.87B18.29B
FY200031 Dec 20000.345.41B16.08B
FY199931 Dec 19990.807.07B8.89B
FY199831 Dec 19980.373.26B8.81B
FY199731 Dec 19970.382.98B7.93B
FY199631 Dec 19960.422.92B6.95B
FY199531 Dec 19950.522.87B5.51B
FY199431 Dec 19940.652.82B4.32B
FY199331 Dec 19930.451.75B3.87B
FY199231 Dec 19920.391.82B4.72B
FY199131 Dec 19910.422.09B5.03B
FY199031 Dec 19900.331.69B5.09B
FY198931 Dec 19890.381.72B4.54B
FY198831 Dec 19880.281.19B4.30B
FY198731 Dec 19870.25963.80M3.88B
FY198631 Dec 19860.16556.70M3.42B
FY198531 Dec 19850.17509.40M2.93B

Figures in USD. A quarter's revenue, net income and dividends are those of its last four quarters.

See also:P/E ratio,Market cap,P/S ratio,Dividend yield,ROE (return on equity),Current ratio,All ratios

Common questions about Pfizer's debt to equity

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.